ArticleInternational journal of nanomedicine2018
Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- A highly biocompatible self-assembled Pt(IV) nanoplatform integrating Nrf2 inhibition for synergistic apoptosis and ferroptosis in hepatocellular carcinoma.Materials today. Bio · 2026Article
- Scalable microfluidic fabrication of optimized phospholipid nanocarriers for enhanced topical bioavailability: Analytical QbD integration andInternational journal of pharmaceutics: X · 2026Article
- Nano Biomaterials in Drug Delivery and Tissue Engineering.Current drug delivery · 2026Review
- Biomimetic nanoparticles for targeted therapy of liver disease.RSC pharmaceutics · 2025Review
- Integrated network toxicology, machine learning algorithms and TMT proteomics reveal the mechanism of 18β glycyrrhetinic acid against gastric cancer.Frontiers in genetics · 2025Article
- Evaluation of the liver targeting and anti‑liver cancer activity of artesunate‑loaded and glycyrrhetinic acid‑coated nanoparticles.Experimental and therapeutic medicine · 2023Article
- Gypsogenin Battling for a Front Position in the Pentacyclic TriterpenesMolecules (Basel, Switzerland) · 2023Review
- Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy.Molecules (Basel, Switzerland) · 2022Review
- Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.Journal of nanobiotechnology · 2022Review
- Drug delivery strategy in hepatocellular carcinoma therapy.Cell communication and signaling : CCS · 2022Review
- The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges.International journal of molecular sciences · 2022Review
- A nano-preparation approach to enable the delivery of daphnoretin to potentiate the therapeutical efficacy in hepatocellular cancer.Frontiers in pharmacology · 2022Article
- Analysis of the network pharmacology and the structure-activity relationship of glycyrrhizic acid and glycyrrhetinic acid.Frontiers in pharmacology · 2022Article
- Preparation of docetaxel-loaded, glycyrrhetinic acid-modified nanoparticles and their liver-targeting and antitumor activity.Experimental and therapeutic medicine · 2021Article
- Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis.International journal of nanomedicine · 2021Article
- Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.International journal of nanomedicine · 2019Article
- Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy.International journal of nanomedicine · 2019Article
- Targeted Delivery of Paclitaxel in Liver Cancer Using Hyaluronic Acid Functionalized Mesoporous Hollow Alumina Nanoparticles.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are abundant glycyrrhetinic acid (GA) receptors on the cellular membrane of hepatocytes and hepatocellular carcinoma (HCC) cells. The receptor binding effect might be related to the structure of the guiding molecule. GA exists in two stereoisomers with C3-hydroxyl and C11-carbonyl active groups. PURPOSE: The objective of this study was to investigate the relationship between the HCC-targeted effect and the configurations and groups of GA. METHODS AND
resultsDifferent GA derivatives (18β-GA, 18α-GA, 3-acetyl-18β-GA [3-Ace-GA] and 11-deoxy-18β-GA [11-Deo-GA]) were used to investigate the targeting effect of GA's configurations and groups on HCC cells. The EC
conclusionThe β-configuration hydrogen atom on C18 position of GA played the most important role on the targeting effect. C11-carbonyl and C3-hydroxy groups of GA have certain and little influence on targeting action to HCC, respectively. In general, GA might be a promising targeting molecule for the research on liver diseases and hepatoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.